Sanofi successfully prices EUR 8 billion of bond issues

	Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)
Sanofi successfully prices EUR 8 billion of bond issues Paris, France - March 15, 2018 - Sanofi has successfully priced its offering of EUR 8 billion of notes (the "Notes") across 6 tranches: €1.0 billion floating rate notes, due March 2020, bearing interest at a quarterly rate of 3-month EURIBOR + 15 bp €0.5 billion fixed rate notes, due March 2020, bearing interest at an annual rate of 0.0% €1.75 billion fixed rate notes, due March 2023, bearing interest at an annual rate of 0.5% €1.5 billion fixed rate notes, due March 2026, bearing interest at an annual rate of 1.0% €2.0 billion fixed rate notes, due March 2030, bearing interest at an annual rate of 1.375% €1.25 billion fixed rate notes, due March 2038, bearing interest at an annual rate of 1.875% The issues are made under the company's Euro Medium Term Note Programme. The transaction enables the company to lower its average cost of debt and extend the average maturity of its debt. Sanofi intends to use the net proceeds of the offering for general corporate purposes, including the financing of the acquisitions of Bioverativ and Ablynx. BNP Paribas, Société Générale CIB and UniCredit Bank acted as Global Coordinators and Bookrunners, alongside Crédit Agricole CIB, Citi, HSBC, ING, J.P. Morgan, RBC Capital Markets and Santander which acted as Bookrunners for the offering.
About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life
Media Relations Contact Laurence Bollack Tel.: [phone] [e-mail]